ETF Holdings Breakdown of ITCI

Stock NameIntracellular Th
TickerITCI(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS46116X1019
LEI5299002U2KGF193IJA20

News associated with ITCI

StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)
Investment analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research report issued to clients and investors on Wednesday. The firm set a “hold” rating on the biopharmaceutical company’s stock. Other equities analysts have also issued research reports about the stock. Piper Sandler reissued a “neutral” rating […] - 2025-05-09 05:14:56
MetLife Investment Management LLC Sells 145 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
MetLife Investment Management LLC trimmed its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 2.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 6,343 shares of the biopharmaceutical company’s stock after selling 145 shares during the period. MetLife […] - 2025-05-06 08:01:00
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.com
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a research report report published on Tuesday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. A number of other brokerages have also recently weighed in on ITCI. Cantor Fitzgerald reiterated a “neutral” rating and set a $132.00 price […] - 2025-04-30 07:44:58
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Mariner LLC
Mariner LLC lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 7.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 10,497 shares of the biopharmaceutical company’s stock after purchasing an additional 758 shares during the period. Mariner LLC’s holdings in Intra-Cellular Therapies were worth $877,000 at the end […] - 2025-04-29 08:00:50
Sterling Capital Management LLC Has $139,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Sterling Capital Management LLC decreased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 11.1% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,663 shares of the biopharmaceutical company’s stock after selling 207 shares during the quarter. Sterling […] - 2025-04-22 08:16:58
Intra-Cellular Therapies (NASDAQ:ITCI) Earns Hold Rating from Analysts at StockNews.com
StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Free Report) in a report published on Monday. The brokerage issued a hold rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on the company. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and cut their price […] - 2025-04-22 05:48:50
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Decreased by Russell Investments Group Ltd.
Russell Investments Group Ltd. reduced its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 39.4% during the fourth quarter, Holdings Channel reports. The firm owned 32,306 shares of the biopharmaceutical company’s stock after selling 21,017 shares during the period. Russell Investments Group Ltd.’s holdings in Intra-Cellular Therapies were worth $2,698,000 at the end […] - 2025-04-18 08:26:53
Envestnet Asset Management Inc. Sells 2,317 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Envestnet Asset Management Inc. cut its stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 1.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 131,662 shares of the biopharmaceutical company’s stock after selling 2,317 shares during the period. Envestnet Asset […] - 2025-04-18 07:45:00
Legal & General Group Plc Sells 8,681 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Legal & General Group Plc cut its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 5.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 149,161 shares of the biopharmaceutical company’s stock after selling 8,681 shares during […] - 2025-04-17 09:08:51
StockNews.com Initiates Coverage on Intra-Cellular Therapies (NASDAQ:ITCI)
Equities researchers at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a research note issued to investors on Sunday. The firm set a “hold” rating on the biopharmaceutical company’s stock. ITCI has been the subject of a number of other research reports. Mizuho downgraded shares of Intra-Cellular Therapies from […] - 2025-04-15 05:16:49
Cantor Fitzgerald Reiterates “Neutral” Rating for Intra-Cellular Therapies (NASDAQ:ITCI)
Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report)‘s stock had its “neutral” rating reaffirmed by research analysts at Cantor Fitzgerald in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $132.00 price objective on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective points to a potential upside of 0.10% from the company’s […] - 2025-04-04 05:56:51
Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $106.08
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) has been assigned an average recommendation of “Hold” from the fifteen ratings firms that are covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the […] - 2025-04-02 06:09:06
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Acquired by Vanguard Group Inc.
Vanguard Group Inc. increased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 1.0% during the 4th quarter, Holdings Channel reports. The fund owned 9,721,360 shares of the biopharmaceutical company’s stock after purchasing an additional 93,107 shares during the quarter. Vanguard Group Inc. owned approximately 0.09% of Intra-Cellular Therapies worth $811,928,000 […] - 2025-03-30 09:28:47
19,043 Shares in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Acquired by Proficio Capital Partners LLC
Proficio Capital Partners LLC purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the 4th quarter, Holdings Channel reports. The firm purchased 19,043 shares of the biopharmaceutical company’s stock, valued at approximately $1,590,000. A number of other institutional investors also recently bought and sold shares of ITCI. Wasatch Advisors […] - 2025-03-20 07:50:52
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Position Lowered by PNC Financial Services Group Inc.
PNC Financial Services Group Inc. decreased its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 4.3% during the 4th quarter, HoldingsChannel.com reports. The firm owned 8,034 shares of the biopharmaceutical company’s stock after selling 357 shares during the quarter. PNC Financial Services Group Inc.’s holdings in Intra-Cellular Therapies were worth $671,000 […] - 2025-03-19 08:03:17
SCHA, ITCI, AFRM, EXEL: Large Outflows Detected at ETF
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab US Small-Cap ETF (Symbol: SCHA) where we have detected an approximate $550.8 million dollar outflow -- that's a 3.3% decrease week over week - 2025-03-17 14:52:32
M&T Bank Corp Purchases 138 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
M&T Bank Corp grew its position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 2.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 6,301 shares of the biopharmaceutical company’s stock after purchasing an additional 138 shares during the quarter. M&T […] - 2025-03-14 08:54:58
Assetmark Inc. Has $191,000 Holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Assetmark Inc. cut its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 7.8% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 2,284 shares of the biopharmaceutical company’s stock after selling 193 shares during the quarter. Assetmark Inc.’s holdings in Intra-Cellular Therapies […] - 2025-03-14 07:56:54
Intra-Cellular Therapies (NASDAQ:ITCI) Now Covered by StockNews.com
Investment analysts at StockNews.com started coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a report issued on Wednesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock. Several other analysts have also issued reports on ITCI. Mizuho lowered Intra-Cellular Therapies from an “outperform” rating to a “neutral” rating and […] - 2025-03-12 06:19:01
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by Charles Schwab Investment Management Inc.
Charles Schwab Investment Management Inc. raised its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 0.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 906,646 shares of the biopharmaceutical company’s stock after acquiring an additional 1,737 shares during the […] - 2025-03-11 08:32:53
Jones Financial Companies Lllp Has $550,000 Position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Jones Financial Companies Lllp raised its position in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 71.6% in the 4th quarter, Holdings Channel.com reports. The firm owned 6,590 shares of the biopharmaceutical company’s stock after buying an additional 2,750 shares during the period. Jones Financial Companies Lllp’s holdings in Intra-Cellular Therapies were worth $550,000 at […] - 2025-03-11 07:44:50
Proficio Capital Partners LLC Purchases Shares of 19,043 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Proficio Capital Partners LLC purchased a new stake in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 19,043 shares of the biopharmaceutical company’s stock, valued at approximately $1,590,000. A number of other institutional investors and hedge funds […] - 2025-03-07 09:26:52
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Bought by New York State Common Retirement Fund
New York State Common Retirement Fund lifted its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 7.2% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,563 shares of the biopharmaceutical company’s stock after purchasing an additional 5,162 shares during the […] - 2025-02-27 08:51:02
CIBC Asset Management Inc Purchases 150 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
CIBC Asset Management Inc grew its stake in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 5.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,956 shares of the biopharmaceutical company’s stock after buying an additional 150 shares during the […] - 2025-02-26 08:52:53
Intra-Cellular Therapies (NASDAQ:ITCI) Coverage Initiated by Analysts at StockNews.com
Investment analysts at StockNews.com began coverage on shares of Intra-Cellular Therapies (NASDAQ:ITCI – Get Free Report) in a report issued on Monday. The firm set a “hold” rating on the biopharmaceutical company’s stock. A number of other brokerages have also weighed in on ITCI. Piper Sandler reaffirmed a “neutral” rating and issued a $132.00 target […] - 2025-02-24 07:14:57
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Sold by Mirae Asset Global Investments Co. Ltd.
Mirae Asset Global Investments Co. Ltd. trimmed its holdings in Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 7.6% in the fourth quarter, HoldingsChannel.com reports. The firm owned 3,533 shares of the biopharmaceutical company’s stock after selling 289 shares during the quarter. Mirae Asset Global Investments Co. Ltd.’s holdings in Intra-Cellular Therapies were worth $300,000 […] - 2025-02-14 08:30:50
Wilmington Savings Fund Society FSB Acquires 740 Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)
Wilmington Savings Fund Society FSB increased its holdings in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Free Report) by 55.7% in the fourth quarter, Holdings Channel.com reports. The firm owned 2,069 shares of the biopharmaceutical company’s stock after purchasing an additional 740 shares during the quarter. Wilmington Savings Fund Society FSB’s holdings in Intra-Cellular Therapies […] - 2025-02-13 08:52:56

ITCI institutional holdings

The following institutional investment holdings of ITCI have been identified

Date ETF ISIN/Name Num Shares Book value
2025-04-02 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 59,253USD 7,813,693
2025-04-02 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 38,191USD 5,036,247
2025-04-02 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 121,905USD 16,075,612
2025-03-31 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 51,557 -1.0%USD 6,801,399 -0.9%
2025-03-31 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 51,557 -1.0%USD 6,801,399 -0.9%
2025-04-02 IE000NITTFF2 (iShares Russell 1000 Growth UCITS ETF) 908USD 119,856 0.1%
2025-04-02 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 624USD 82,287
Total =323,995 USD 42,730,493
Book value of shares is calculated on the adjusted close price of each day (row).

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.